ESTA

Establishment Labs Holdings Inc. (ESTA) | Rumor.io

Establishment Labs Holdings

ESTA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,437

Bullish sentiment (50-day avg)100%

Price to earnings ratio-38

Market capitalization1.9B

Earnings per share-1.27

Dividend yield (TTM)—

Revenue (annual)211.1M

Net income (annual)-51.1M

Social

What share of all stock conversation is about ESTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

May 19

Establishment Labs Holdings Inc. (ESTA) has seen unusual market activity, with some speculating about its potential involvement in the next market cycle.
There is no direct market commentary or analysis on ESTA in the provided posts.
No specific financial or market-related information about ESTA is mentioned in the posts.

Generated by AI

Sentiment

Of the messages about ESTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	99.41% +8.7
Bearish	—	0%	0% 0	0.59% -8.7

Bullish· Nov 5

ESTA is expected to take a 20% share of the US breast augmentation market and exceed its previous guidance of $40 million in US Motiva sales.
The company has achieved positive adjusted EBITDA ahead of schedule, driven by strong US growth, and is now focusing on reaching cash flow positive next year.
ESTA's Q3 2025 earnings report showed a 16% sequential growth in the US, with the fourth quarter being the strongest quarter for breast augmentation, and the company is expecting another strong year of growth in 2026.

Bearish· Nov 8

Establishment Labs Holdings Inc. (ESTA) reported a 75% decline in net income margin, with a loss of $29 million despite $38 million in revenue.
The company's full-year guidance was cut, and its third-quarter loss from operations increased to $21 million from $10.5 million in the year-ago period.
ESTA's stock price has plummeted from $72 to $19.49 in just 90 days, indicating a significant decline in investor confidence.

Generated by AI

Topics

Of the messages about ESTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	100%	100%	23.73%
Technical Analysis	—	0%	0%	19.77%
Announcements	—	0%	0%	49.15%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	5.65%
Macro	—	0%	0%	1.69%

Announcements· Sep 27

Establishment Labs Holdings' ($ESTA) shares jumped 30% in premarket trading after the FDA approved its Motiva breast implants.
The FDA's approval is a major milestone for ESTA, and the company's products launching in the US is expected to drive significant revenue growth in FY25.
The US breast implant market has entered the Motiva era, with ESTA's implant expected to take share and drive meaningful revenue growth acceleration due to its compelling safety and aesthetic profile.

Controversies· Oct 20

* $ESTA Establishment Labs Holdings Inc. is facing a shareholder investigation due to potential losses, with law firms encouraging affected shareholders to contact them.
* Johnson Fistel and Hagens Berman, two law firms, are investigating Establishment Labs Holdings Inc. over potential losses, with some posts suggesting the company may have engaged in wrongdoing.
* The company's stock performance and potential lawsuits are being compared to those of larger companies, such as Pfizer, with some suggesting that Establishment Labs may be targeted due to its smaller size and lower market capitalization.

Generated by AI

Community

Of the messages about ESTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	5.88%	14.95%
Newcomers	—	0%	94.12%	85.05%

Regulars· Oct 19

Regulars are concerned about the debt carried by ESTA, pointing out that 99% of biotech companies without US approval have debt 10-20x higher than ESTA's, yet they're not being shorted.
The high IV (implied volatility) of 96.23% on the $50.00 Nov 18 2022 CALL suggests that many traders expect a significant price move in ESTA.
ESTA's decline in premarket trading is notable, with the SEC being criticized for not investigating potential wrongdoing, and a nationally ranked investors' rights firm announcing an investigation into ESTA.

Newcomers· Sep 27

The FDA has granted approval for Establishment Labs' Motiva breast implants, which could lead to significant growth for ESTA shares.
ESTA shares have jumped nearly 30% in premarket trading after the FDA approval, with some analysts expecting the stock to continue to rise.
The high short interest in ESTA shares, combined with the FDA approval, could lead to a "squeeze" that drives the stock price even higher.

Generated by AI

For growth investors, Establishment Labs Holdings (NASDAQ:ESTA) presents a compelling equity thesis: a medical aesthetics disruptor transitioning from cash-burning expansion to sustainable, profitable scale. Evaluating the company’s long-term fundamentals, such as its trajectory of multi-year revenue growth, operating cash flow generation, return on invested capital/ROIC, and ultimate free cash flow conversion, reveals a business at […]

6d agoYahoo Finance

Establishment Labs presents clinical data, expands product lines

8d agoInvesting.com

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants

NEW YORK, September 21, 2026--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of new clinical and scientific data supporting Breast Tissue Preservation and its Minimally Invasive Platform. Establishment Labs also announced the product line extensions of both Mia® and Preservé™ with new sizes and supporting tools. The announcement

9d agoYahoo Finance

Establishment Labs: Procedure Economics Strengthens The Bull Case (NASDAQ:ESTA)

21d agoSeeking Alpha

Analysts Offer Insights on Healthcare Companies: McKesson (MCK), uniQure (QURE) and Establishment Labs Holdings (ESTA)

Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.

27d agoThe Globe and Mail

Looking for under-the-radar stocks? Cramer gives his take on 5 unfamiliar names

CNBC's Jim Cramer took a fresh look at five stocks viewers asked about, including ExlService, MakeMyTrip, Establishment Labs, NVE and Ubiquiti.

1mo agoCNBC

Also Discussed

Investors talking about ESTA also mention

#	Name	Attention
1	BFIN - BankFinancial Corporation	——
2	STAAR Surgical CompanySTAA	0%new
3	Primoris Services CorporationPRIM	0%0
4	SPDR DoubleLine Total Return Tactical ETFTOTL	0%new
5	Martin Midstream Partners L.P.MMLP	0%new
6	Calamos Russell 2000 Structured Alt Protection ETF - OctoberCPRO	0%0
7	Femasys Inc.FEMY	0%+0
8	TBIO - Telesis Bio, Inc.	——
9	ARKO Corp.ARKO	0.01%new
10	Brookfield Infrastructure Partners L.P. Preferred Stock 5.125% PerpetualBIPI	0%new

Establishment Labs Holdings Inc.

Healthcare
Medical Devices

Establishment Labs Holdings Inc. is a medical technology company focused on breast aesthetics and reconstructive plastic surgery. Its core portfolio includes silicone gel-filled breast implants under the Motiva Implants brand, along with breast tissue expanders and related surgical technologies used in augmentation and reconstruction procedures. The company serves physicians, hospitals, and clinics through a combination of direct sales and distributor networks, supporting commercial activity across Europe, the Middle East, Africa, Latin America, Asia, and the United States. Establishment Labs Holdings Inc. also develops products and platforms designed to support surgical planning and procedural workflows in aesthetic and reconstructive care. Headquartered in Austin, Texas, the company plays a specialized role in the global medical device market by supplying devices centered on women’s health, breast reconstruction, and aesthetic surgery.

Website

Location

11401 century oaks terrace

Austin, TX, 78758

United States

Social

What share of all stock conversation is about ESTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

May 19

Establishment Labs Holdings Inc. (ESTA) has seen unusual market activity, with some speculating about its potential involvement in the next market cycle.
There is no direct market commentary or analysis on ESTA in the provided posts.
No specific financial or market-related information about ESTA is mentioned in the posts.

Generated by AI

Sentiment

Of the messages about ESTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	99.41% +8.7
Bearish	—	0%	0% 0	0.59% -8.7

Bullish· Nov 5

ESTA is expected to take a 20% share of the US breast augmentation market and exceed its previous guidance of $40 million in US Motiva sales.
The company has achieved positive adjusted EBITDA ahead of schedule, driven by strong US growth, and is now focusing on reaching cash flow positive next year.
ESTA's Q3 2025 earnings report showed a 16% sequential growth in the US, with the fourth quarter being the strongest quarter for breast augmentation, and the company is expecting another strong year of growth in 2026.

Bearish· Nov 8

Establishment Labs Holdings Inc. (ESTA) reported a 75% decline in net income margin, with a loss of $29 million despite $38 million in revenue.
The company's full-year guidance was cut, and its third-quarter loss from operations increased to $21 million from $10.5 million in the year-ago period.
ESTA's stock price has plummeted from $72 to $19.49 in just 90 days, indicating a significant decline in investor confidence.

Generated by AI

Topics

Of the messages about ESTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	100%	100%	23.73%
Technical Analysis	—	0%	0%	19.77%
Announcements	—	0%	0%	49.15%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	5.65%
Macro	—	0%	0%	1.69%

Announcements· Sep 27

Establishment Labs Holdings' ($ESTA) shares jumped 30% in premarket trading after the FDA approved its Motiva breast implants.
The FDA's approval is a major milestone for ESTA, and the company's products launching in the US is expected to drive significant revenue growth in FY25.
The US breast implant market has entered the Motiva era, with ESTA's implant expected to take share and drive meaningful revenue growth acceleration due to its compelling safety and aesthetic profile.

Controversies· Oct 20

* $ESTA Establishment Labs Holdings Inc. is facing a shareholder investigation due to potential losses, with law firms encouraging affected shareholders to contact them.
* Johnson Fistel and Hagens Berman, two law firms, are investigating Establishment Labs Holdings Inc. over potential losses, with some posts suggesting the company may have engaged in wrongdoing.
* The company's stock performance and potential lawsuits are being compared to those of larger companies, such as Pfizer, with some suggesting that Establishment Labs may be targeted due to its smaller size and lower market capitalization.

Generated by AI

Community

Of the messages about ESTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	5.88%	14.95%
Newcomers	—	0%	94.12%	85.05%

Regulars· Oct 19

Regulars are concerned about the debt carried by ESTA, pointing out that 99% of biotech companies without US approval have debt 10-20x higher than ESTA's, yet they're not being shorted.
The high IV (implied volatility) of 96.23% on the $50.00 Nov 18 2022 CALL suggests that many traders expect a significant price move in ESTA.
ESTA's decline in premarket trading is notable, with the SEC being criticized for not investigating potential wrongdoing, and a nationally ranked investors' rights firm announcing an investigation into ESTA.

Newcomers· Sep 27

The FDA has granted approval for Establishment Labs' Motiva breast implants, which could lead to significant growth for ESTA shares.
ESTA shares have jumped nearly 30% in premarket trading after the FDA approval, with some analysts expecting the stock to continue to rise.
The high short interest in ESTA shares, combined with the FDA approval, could lead to a "squeeze" that drives the stock price even higher.

Generated by AI

Establishment Labs Holdings

Social

May 19

Bullish· Nov 5

Bearish· Nov 8

Announcements· Sep 27

Controversies· Oct 20

Regulars· Oct 19

Newcomers· Sep 27

Is Establishment Labs’ (ESTA) Profitability Inflection the Ultimate Buying Opportunity?

Establishment Labs presents clinical data, expands product lines

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants

Establishment Labs: Procedure Economics Strengthens The Bull Case (NASDAQ:ESTA)

Analysts Offer Insights on Healthcare Companies: McKesson (MCK), uniQure (QURE) and Establishment Labs Holdings (ESTA)

Looking for under-the-radar stocks? Cramer gives his take on 5 unfamiliar names

Also Discussed

Establishment Labs Holdings Inc.

Company Information

Location

Is Establishment Labs’ (ESTA) Profitability Inflection the Ultimate Buying Opportunity?

Establishment Labs presents clinical data, expands product lines

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants

Establishment Labs: Procedure Economics Strengthens The Bull Case (NASDAQ:ESTA)

Analysts Offer Insights on Healthcare Companies: McKesson (MCK), uniQure (QURE) and Establishment Labs Holdings (ESTA)

Looking for under-the-radar stocks? Cramer gives his take on 5 unfamiliar names

Also Discussed

Social

May 19

Bullish· Nov 5

Bearish· Nov 8

Announcements· Sep 27

Controversies· Oct 20

Regulars· Oct 19

Newcomers· Sep 27